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Abstract
Introduction: A number of antiretroviral HIV prevention products are efficacious in preventing HIV infection. However, the
sexual and reproductive health needs of many women extend beyond HIV prevention, and research is ongoing to develop mul-
ti-purpose prevention technologies (MPTs) that offer dual HIV and pregnancy protection. We do not yet know if these prod-
ucts will be an efficient use of constrained health resources. In this paper, we estimate the cost-effectiveness of combinations
of candidate multi-purpose prevention technologies (MPTs), in South Africa among general population women and female sex
workers (FSWs).
Methods: We combined a cost model with a static model of product impact based on incidence data in South Africa to esti-
mate the cost-effectiveness of five candidate co-formulated or co-provided MPTs: oral PrEP, intravaginal ring, injectable ARV,
microbicide gel and SILCS diaphragm used in concert with gel. We accounted for the preferences of end-users by predicting
uptake using a discrete choice experiment (DCE). Product availability and protection were systematically varied in five poten-
tial rollout scenarios. The impact model estimated the number of infections averted through decreased incidence due to pro-
duct use over one year. The comparator for each scenario was current levels of male condom use, while a health system
perspective was used to estimate discounted lifetime treatment costs averted per HIV infection. Product benefit was esti-
mated in disability-adjusted life years (DALYs) averted. Benefits from contraception were incorporated through adjusting the
uptake of these products based on the DCE and through estimating the costs averted from avoiding unwanted pregnancies.
We explore the additional impact of STI protection through increased uptake in a sensitivity analysis.
Results: At central incidence rates, all single- and multi-purpose scenarios modelled were cost-effective among FSWs and
women aged 16–24, at a governmental willingness-to-pay threshold of $1175/DALY averted (range: $214–$810/DALY averted
among non-dominant scenarios), however, none were cost-effective among women aged 25–49 (minimum $1706/DALY
averted). The cost-effectiveness of products improved with additional protection from pregnancy. Estimates were sensitive to
variation in incidence assumptions, but robust to other parameters.
Conclusions: To the best of our knowledge, this is the first study to estimate the cost-effectiveness of a range of potential
MPTs; suggesting that MPTs will be cost-effective among higher incidence FSWs or young women, but not among lower inci-
dence older women. More work is needed to make attractive MPTs available to potential users who could use them effectively.
Keywords: discrete choice experiments; HIV prevention; key populations; multi-purpose prevention; pre-exposure prophylaxis;
South Africa
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1 | INTRODUCTION
Over the past six years, clinical trials have shown that
antiretroviral (ARV)-based pre-exposure prophylaxis (PrEP)
can be efficacious in preventing the transmission of human
immunodeficiency virus (HIV) [1–5]. However, protection
has been variable during clinical trials and different PrEP
modalities have conferred substantially less protection to
younger women than older women [4,6]. Both oral and
topical PrEP products have been more effective in male
populations than females [7,8], partly explained by adher-
ence, and partly by pharmacokinetic data indicating higher
drug colorectal drug concentrations than in the female
lower genital tract [6,9].
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It is likely that more than one effective prevention option
will be needed to achieve population coverage among women
[10]. One option to increase impact while making products
more desirable to potential users is to develop multi-purpose
prevention technologies (MPTs), which simultaneously provide
protection from two or more of HIV, other STIs and unin-
tended pregnancy [11–14]. Current MPTs in development
include: (1) long-acting drug delivery systems such as intrav-
aginal rings, designed to protect from HIV infection and
pregnancy (currently in phase-1 trial, ClinicalTrials.gov Identi-
fier: NCT02235662); (2) pericoital drug delivery systems
such as vaginal gels, tablets and films (not currently being
trialled); and (3) co-provision of a combination of products,
such as a contraceptive diaphragm with microbicide gel (cur-
rently feasible but not widely implemented) [11,15]. In the
medium term, the co-provision of contraceptive and HIV pre-
ventative products could be an intermediate step to the
development of a MPT. As HIV prevention products come to
market, provision alongside contraceptives – particularly
when products are of the same modality – could facilitate
uptake and adherence, and gauge demand for potential MPTs
in the future.
Despite large variations in effectiveness and cost assump-
tions, previous studies have broadly found single-purpose
PrEP to be cost-effective when delivered to populations at
high risk of HIV infection [16–20]. Although the financial and
regulatory burden of MPT development is likely to be high,
their benefits may also be large, not least because of synergis-
tic impacts across health outcomes. Firstly, products offering
more than one indication may be more attractive to some
potential users than single-purpose products, particularly the
combination of contraceptive and HIV prevention properties
[21,22]. Secondly, MPT use could crowd-in protection from les-
ser valued attributes. For example, where users value contra-
ceptive properties strongly, additional HIV protection would
be a positive externality from the use of a dual-protective
product. In addition, we can use lessons learnt in contracep-
tive provision for different female populations to optimise
MPT or co-provision modalities [23]. Thirdly, the contraceptive
properties of MPTs may reduce the stigma associated with
accessing HIV prevention tools, shown to be a substantive
barrier to use [24,25].
Unlike other PrEP impact models which use expert opinion
to inform uptake assumptions, we take a data-driven approach
using a discrete choice experiment (DCE) to predict product
uptake among different groups [26]. DCEs are economic tools
which ask people to choose between hypothetical alternatives,
and have been shown reliable when predicting real-world
choices [27,28]. Although relying on hypothetical choices, a
DCE is useful because preferences can be elicited for prod-
ucts which do not exist yet, thus we can estimate demand for
co-formulated or co-provided products containing contracep-
tive properties. DCEs are objective, end-user focused tools
which may be less biased than predictions based on expert
opinion [28,29].
This paper presents a cost-effectiveness analysis which esti-
mates the incremental benefits and health system costs of
single- and multi-purpose prevention products, compared to
current practice of condom use and male circumcision preva-
lence. Cost-effectiveness is modelled across three female
groups due to differences in epidemiology and HIV risk in
each: younger women (aged 16–24), older women (aged 25–
49) and female sex workers (FSWs).
2 | METHODS
2.1 | Analytic overview
This analysis builds on previous work using a DCE to elicit
preferences for new HIV prevention products in South Africa
[29]. Figure 1 displays our approach to estimate the cost-
effectiveness of the five single and multi-purpose prevention
products considered: oral PrEP, intravaginal rings, injectable
ARVs, microbicide gels and SILCS diaphragms used in concert
with gel. A full list of parameters used in the model is pre-
sented in File S1. In this paper, we focus on contraceptive
MPTs (considering STI prevention in a sensitivity analysis)
because no STI-specific MPT is in development while there
are limited data on the efficacy of MPT products to prevent
STIs. We model cost and benefits associated with one-year’s
products use, and therefore do not consider variations over
time such as increasing economies of scale or diminishing
adherence patterns.
2.2 | Estimating uptake
DCE data were gathered in Ekurhuleni Municipality, South
Africa between September and December 2015 from 484
self-reported HIV-negative women: 362 from the general pop-
ulation and 122 FSWs. We use DCE data to simulate uptake
for different scenarios of MPT characteristics (Table 1) in
each population. In the model, users choose one product (or
continue current practice) from a set, where availability is
defined by different policy scenarios set out in the next sec-
tion. The DCE protocol and results are described in detail
elsewhere [26,30], while further information is given in File
S2.
2.3 | Rollout scenarios
We modelled product uptake for five rollout scenarios that
differed in product characteristics and availability. Table 2
shows the scenarios modelled, for all of which we use current
practice as the base case for comparison. Scenario 1 is the
most likely to occur first, as single-purpose oral PrEP is
already available to FSW groups in South Africa [36]. Cau-
tiously positive results from intravaginal ring trials [5] indicate
that a single-purpose ring with HIV prevention may be intro-
duced next, while a multi-purpose ring could be available in
the medium term; we refer to this MPT ring plus PrEP sce-
nario as scenario 3 [11]. Finally, we model the introduction of
a varied suite of single then multi-purpose products in scenar-
ios 4 and 5 respectively. Although poor efficacy in clinical tri-
als has seen the HIV prevention field move away from
microbicide gels [8], we include them here to inform the
development of other topical ARV-based preventative meth-
ods, including vaginal tablets or films [37].
2.4 | Estimating HIV protection
To be conservative, and to focus on differences between pop-
ulations and the relative preferences for different products,
Quaife M et al. Journal of the International AIDS Society 2018, 21:e25064
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25064/full | https://doi.org/10.1002/jia2.25064
2
we do not model temporal reductions in the overall level of
HIV transmission due to long- term product use. Instead, we
model the yearly impact of introducing each product scenario
among three female population groups in South Africa, and
compare the total and incremental costs and benefits of each
introduction scenario.
We use formula (1) to estimate the impact of each pro-
duct scenario on the average level of protection conferred
to an individual [29,38]. This measure gives the average
decrease in HIV transmission probability across a
population for an average sex act, combining the protec-
tion provided from several products with different effica-
cies being used at different levels. For a single product x,
we assume the average protection against HIV, px, from
using product x is a function of its efficacy, Ex, and uptake
(or use) Ux,
Figure 1. Modelling schematic.
Table 1. Product characteristics
Product characteristics
HIV efficacy
(%, Ex), [PSA
bounds]
Contraceptive
protection
Frequency
of use
Product cost
assumptions ($USD) Source
Single-purpose Direct cost of single
purpose ARV product
Oral PrEP 61 [40–75] N Daily 75 [70–130]
(/person-year)
[19,31,32]
Microbicide gel 55 [31–71] N Coitally 3.69 [3–4.5] (/tube)b Manufacturer
(Kessel [33])
SILCS diaphragm 55 [31–71]a N Coitally 5.19 [4–6]
(/diaphragm)
Manufacturer
(Kessel [33])
Vaginal ring 55 [31–71] N Monthly 6 [5–7] (/ring) Distributor
(IPM [34])
Injectable ARV agent 75 [55–90] N Three monthly 6 [5–7] (/injection) Assumption from
vaginal ring
No condom 0 N Coital N/A (comparator)
Multi-purpose Marginal direct cost of
contraceptive compound
Male condom 95 [66–94] Y Coital N/A (comparator)
MPT oral PrEP 61 [40–75] Y Daily 8.72 [6.17–11.5]
(/person-year)
[35]
MPT microbicide gel 55 [31–71] Y Coitally 9.14 [6.4–12]
(/person-year)
[35]
SILCS diaphragm & microbicide gel 55 [31–71]a Y Coitally –
MPT vaginal ring 55 [31–71] Y Monthly 9.14 [6.4–12]
(/person-year)
Assumed equal to
highest cost product
(injectable) [35]
Injectable MPT agent 75 [55–90] Y Three monthly 9.14 [6.4–12]
(/person-year)
[35]
aDue to co-use, the efficacy of the SILCS diaphragm was assumed the same as the microbicide gel; bAssumptions on product use and other associ-
ated costs of provision listed fully in File S3.
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px ¼ ExUx ð1Þ
We begin by denoting Px as the existing protection pro-
vided by male condoms with efficacy E0 and consistency of
use U0, before any new products are introduced our DCE
then gives projections of the degree to which condom users
and non-condom users (defined by use at last sex act)
uptake each new product in each scenario s, and for con-
dom users the probability that the woman still uses the
condom (e) in addition to the new products. For scenarios
involving a number m of new products (denoted by sub-
script i = 1. . .m), each with efficacy Esi and differing uptake
Usic among condom users (c = 1) and non-condom users
(c = 0) respectively, the average protection provided to an
individual in the population due to condoms and the intro-
duction of m new products (not just among users of the
product) is estimated as Psm:
Psm ¼U0 E0 
X
i¼1...m
Usi;1ð1 eÞE0 þ ð1 eÞ
P
i¼1...m
Esi U
s
i;1
þe P
i¼1...m
ð1 E0ÞEsi Usi;1
2
664
3
775
þ ð1 U0Þ
X
i¼1...m
Esi U
s
i;0
ð2Þ
The uptake of each product among condom and non-con-
dom users depends not only on the efficacy of the product
for preventing HIV but also on whether they provide preg-
nancy protection. The prevention protection provided by dif-
ferent products is assumed to be additive. Users are assumed
to use only one new ARV-based prevention product, except
the diaphragm and gel which are necessarily used together
for MPT protection. When condoms are used with a new pro-
duct, the new product was assumed to proportionately
decrease the remaining risk still existing after the 85% protec-
tion provided by the condom [39]. The uptake of each new
product Usic can be defined as uptake multiplied by adherence,
and we vary the latter in a one-way sensitivity analysis and
both in probabilistic sensitivity analysis.
For oral PrEP, we assumed an HIV efficacy of 61% (40–75%
used in probabilistic sensitivity analysis) as found in a recent
meta-analysis of the efficacy of oral PrEP among highly adher-
ent women (>75% adherence) [40]. We then assume that the
vaginal ring is introduced with a HIV efficacy of 55% (31–71%
used in probabilistic sensitivity analysis), as found among older
women in a recent trial [41]. Although some clinical trials of
microbicide gels have shown a lack of efficacy, they have been
shown to be efficacious in others and work continues to
develop a gel which could also offer multi-purpose protection
[11]. We assume that a microbicide gel would not be introduced
if it was less effective than the next-least effective product, in
this case the vaginal ring, and we use the same uncertainty
bounds and allow each to vary in probabilistic simulations. A
higher efficacy for HIV protection of 75% (55–90% used in
probabilistic sensitivity analysis) was assumed for injectable
ARVs because there should be fewer issues of adherence.
2.5 | Estimating DALYs averted through preventing
HIV infection
Our simple impact model estimates the number of infections
averted through one year’s use of different product scenarios,
where incremental protection, Psm , is used to decrease HIV
incidence. We estimate the total discounted lifetime treatment
costs averted from these infections. We use World Bank esti-
mates of the size of the general population in South Africa in
2017 among two female groups aged 16–24 and 25–49 [42]
and apply HIV prevalence estimates from the South African
HSRC National HIV Prevalence, Incidence and Behaviour Sur-
vey 2012 [43] to estimate the HIV negative population in
each group. For FSWs, we used national estimates of FSW
population size and HIV prevalence in South Africa [44,45].
Standard DALY weights are used for HIV/AIDS with and with-
out ART taken from the 2010 Global Burden of Disease study
[46], full details of the DALY calculations are listed in Files S1
and S3.
We obtained group level incidence estimates from national
surveys, as well as from recent HIV treatment and prevention
trials in South Africa [40,43,47,48] presented in Table 3. For
each group, we model scenarios of low, central and high esti-
mates of incidence. The level of protection provided by each
scenario, Psm, is used to model a decrease in incidence:
Incidencenew ¼ Incidencecurrent  ð1 PsmÞ ð3Þ
2.6 | Estimating unintended pregnancies averted
We take the median projected unmet need for contracep-
tion among females in the general population as defined by
the United Nations Population Division [50], and assume
Table 2. Product scenarios modelled
Product(s)
HIV
protection
Pregnancy
protection
Reference
scenario
Current male condom
usage. No ARV-based
single- or multi-purpose
prevention
Scenario 1 Oral PrEP X
Scenario 2 Oral PrEP X
Vaginal ring X
Scenario 3 Oral PrEP X
MPT vaginal ring X X
Scenario 4 Oral PrEP X
Intravaginal ring X
Injectable ARV agent X
Microbicide gel X
SILCS diaphragm &
microbicide gel
X X
Scenario 5 MPT oral PrEP X X
MPT vaginal ring X X
Injectable MPT agent X X
MPT Microbicide gel X X
SILCS diaphragm &
microbicide gel
X X
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that FSWs who report using no method of contraception
have unmet need. Informed by DCE estimates, in the initial
comparison case we assume that 20% of women with
unmet need will use products with contraceptive properties,
and explore how variation in this parameter affects results
in a sensitivity analysis. Following the family planning litera-
ture, DALYs are averted solely from the reduction in esti-
mated maternal mortality from pregnancies averted through
MPT use [51,52].
2.7 | Estimating costs
We estimate costs related to the delivery of a combination
prevention package across all South African public clinics from
a health system perspective. Included intervention costs are
listed in Table 4, and details of their estimation given in File
S3. Products have varying frequencies of collection and use
which we model using realistic clinical use scenarios, informed
by the South African national guidelines for PrEP rollout
among high-risk groups [36]. Where MPT products do not yet
exist, we used existing contraceptive product costs to account
for costs of additional active compounds [35]. Lifetime averted
costs were estimated by multiplying the number of HIV infec-
tions and unwanted pregnancies averted by the discounted
lifetime cost of ART treatment (using estimates of life
expectancy on ART [53]), and delivery, or abortion costs
respectively.
2.8 | Sensitivity analyses
We present results for each group and each scenario at high,
medium and low incidence estimates. In addition, we perform
a series of one-way deterministic sensitivity analyses to
explore how changes in qualitatively important characteristics
affect estimates. Finally, a probabilistic sensitivity analysis
(PSA) explored the sensitivity of our model to a range of
parameter uncertainties, using a Monte Carlo simulation with
1000 draws. Point estimate and distributional assumptions for
the variables included in the PSA are listed in File S1, and
results presented in File S8.
2.9 | Assessment of cost-effectiveness
We assessed the cost-effectiveness of different scenarios by
computing the incremental cost-effectiveness ratio (ICER) for
each intervention: the net costs of an intervention divided by
the number of DALYs averted, and compare this to a willing-
ness-to-pay (WTP) threshold. The South African government
does not have a generally accepted WTP threshold; in the
absence of this we use the threshold estimates of Woods
et al. [54] to represent the opportunity cost of health forgone
from other potential interventions. We took a conservative
stance and applied the lowest estimate, the lower-bound USD
threshold of $1175/DALY averted (range: $1175–$4714),
which was lower than the purchasing-power adjusted range
($2221–$8909) and alternative thresholds such as 19 and
39 GDP/capita [54,55].
3 | RESULTS
3.1 | Deterministic model analysis
Results suggest that co-provision or co-formulation of contra-
ceptive and HIV prevention products will be cost-effective
among younger women and FSWs, but not among older
women. Younger women show distinct preferences for multi-
purpose over single-purpose products as shown in Figure 2
which aggregates uptake among condom and non-condom
users. Notably, we predict that just 8% of women aged 16–
24 would use at least one of the full range of single-purpose
HIV prevention products, however uptake increases by 27
percentage points if products were co-formulated as MPTs.
The predicted uptake of single-purpose products is much
greater among older women (26%) and FSWs (30%), but
additional uptake from including pregnancy protection is rela-
tively low at 7 and 6 percentage points respectively. Where
all products are introduced, the decrease in HIV incidence
attributable to additional uptake due to multi-purpose pro-
tection was higher among younger women (reduction in
19%) than among other groups (8% for older women and
FSWs).
Of the 12.9 million women aged 15–49 in 2017, 10.1 mil-
lion were estimated to be HIV negative [43]. Assuming cen-
tral HIV incidence estimates, 201,552 new HIV infections
are predicted to occur without intervention. Figure 3 illus-
trates DALYs averted for each product scenario among each
population group. We focus here on cost-effectiveness, but
present full impact results in File S6. Net intervention costs
are presented in Figure S7, where rollout among the
Table 3. Estimates of HIV incidence per 100 person years
Low
incidence
Central
incidence
High
incidence References
Females 16–24 1.62 2.54 5.00 [41,48,49]
Female 25–49 1.20 1.62 3.50 [41,48,49]
FSWa 3.50 5.00 8.00 [8]
aNo FSW incidence data found, instead high level female incidence fig-
ures were used.
Table 4. Included intervention costs
Fixed costs National
start-up
costs
Training of providers
Mass media
Variable costs
(based on
predictions
of use)
Facility
distribution
costs
Staff time
Product
Screening tests
Health system
mark-up and
overheads
Averted
health
costs
Antiretroviral treatment
Miscarriages and
births from
unplanned pregnancies
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1.7-times larger population of women aged 25–49 leads to a
four-fold increase in net intervention costs than among those
aged 16–24.
Figure 4 shows ICERs for each product scenario and popu-
lation group. For all groups, oral PrEP plus a MPT intravaginal
ring (Scenario 3) is the most cost-effective scenario modelled,
with an ICER of $563/DALY averted among younger women
and dominating the comparator among FSWs. All scenarios
modelled among women aged 16–24 and among FSWs are
cost-effective when compared to the WTP threshold of
$1175, whilst the no rollout status quo scenario is cost-effec-
tive among women aged 25–49. Among all populations, sce-
narios where multi-purpose products are introduced are more
cost-effective than any combination of single-purpose
products.
These results show the cost-effectiveness of interventions
relative to current levels of condom use, yet the increasing
availability of oral PrEP in South Africa mean that a more
meaningful comparator may be that of oral PrEP provision.
Table 5 displays ICER estimates for introducing single- and
multi-purpose products, with the comparator of oral PrEP and
the range of single-purpose products that may be available.
Again, results indicate that at under all incidence assumptions,
introducing additional ARV-based prevention products will be
cost-effective among women aged 16–24 and FSWs. Results
differ among women aged 25–49, where introducing addi-
tional MPT products is estimated to be cost-effective (in most
cases cost-saving), but adding a single-purpose ring to provi-
sion of single-purpose PrEP is not cost-effective except under
assumptions of high incidence.
3.2 | Sensitivity analyses
Figure 5 shows one-way sensitivity analyses for incidence
assumptions. Our base case model assumptions are repre-
sented by squares, whilst lines to the upper-left and lower-
right demonstrate ICER estimates at lower and upper inci-
dence assumptions respectively. Points to the south-east of
the dashed WTP line are interpreted as cost-effective. In all
but two scenarios modelled (both among FSWs), using an
upper or lower incidence assumption means that the esti-
mated ICER crosses the willingness-to-pay threshold. The inci-
dence level at which the most cost-effective scenario became
cost-ineffective was 1.3, 1.6 and 1.1 infections per 100
person-years for women aged 16–24, 25–49 and FSWs
respectively.
Further one-way sensitivity analyses explored the effect of
parameter uncertainty on model outputs. Tornado plots for
scenario 1 are presented in Figure 6 which became cost-
ineffective among women aged 16–24 and FSWs when
adherence was assumed to be 30%, or if ART coverage was
increased to meet the 90% WHO target [56]. Including STI
preventative attributes in addition to HIV and pregnancy
does not markedly change cost-effectiveness estimates. Tor-
nado plots for the most cost-effective scenario (oral PrEP
plus MPT ring) are included in File S6, and demonstrate
cost-effectiveness in females aged 16–24 and FSWs for all
parameter variations.
MPT cost-effectiveness was broadly robust to reductions
in the assumed efficacy of products. Additional one-way sen-
sitivity analyses (not shown in Figure 6 were carried out on
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Figure 2. Product uptake by group.
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assumptions of product efficacy. Reducing the effectiveness
of all products to 50% meant that all three scenarios of
solely single-purpose products would not be cost-effective
among women aged 16–49 (Scenario 1 had the highest
ICER of $1281), though all MPT scenarios and scenarios
among FSWs would remain cost-effective. MPT scenarios
among younger women were estimated not to be cost-
effective at an efficacy of 45%.
Figure 7 presents cost-effectiveness acceptability curves
for each scenario among each population, while simulation
plots on the cost-effectiveness plane are included in File S7.
For all groups, both scenarios including MPTs were most
-
1,00,000 
2,00,000 
3,00,000 
4,00,000 
5,00,000 
6,00,000 
Scenario 1: Oral PrEP with HIV 
protection only
Scenario 2: Oral PrEP & vaginal ring 
with HIV protection only
Scenario 3: MPT ring plus oral PrEP Scenario 4: All five products with HIV 
protection only
Scenario 5: All five products with 
multipurpose protection
Total DALYs averted: General population
Women 15–24 Women 25–49
-
2,000 
4,000 
6,000 
8,000 
10,000 
Scenario 1: Oral PrEP with HIV 
protection only
Scenario 2: Oral PrEP & vaginal ring 
with HIV protection only
Scenario 3: MPT ring plus oral PrEP Scenario 4: All five products with HIV 
protection only
Scenario 5: All five products with 
multipurpose protection
Total DALYs Averted: FSW
FSW
Figure 3. DALYs averted by population, scenario, and incidence assumption. Coloured bars represent DALYS averted at central incidence
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ences in small FSW population.
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likely to be cost-effective. For older women, younger
women, and FSWs respectively, the model predicts a 0.1%,
71% and 99% probability that the most cost-effective sce-
nario, scenario 3, will be cost-effective. The PSA also con-
firms the primacy of interventions among FSWs and women
aged 16–24, as even the least cost-effective scenario for
each group was 60% likely to be cost-effective at the
$1175 threshold.
4 | DISCUSSION
This study is the first to estimate the cost-effectiveness of a
range of candidate MPT products, and suggests that co-for-
mulated or co-provided MPTs could be an impactful and effi-
cient use of resources. Based on the stated preferences in the
DCE, incorporating contraceptive characteristics into HIV pre-
vention products would result in a meaningful increase in
Table 5. ICER values of comparative scenarios
Incidence assumption
Women 16–24 Women 25–49 FSW
Low Central High Low Central High Low Central High
Single-purpose
Adding vaginal ring to PrEP (Scenario 2
compared to Scenario 1)
$1691 $801 $30 $4763 $3282 $1008 $792 $-66a $-398a
Multi-purpose
Adding MPT ring to PrEP (Scenario
3 compared to Scenario 1)
$727 $243 $-225a $-401a $-482a $-669a $-532a $-709a $-791a
Adding MPT range to single-purpose
range (Scenario 5 compared
to Scenario 4)
$1214 $543 $-79a $88 $-114a $-503a $-1810a $-1502a $-1334a
aNegative ICER values indicate cost-saving interventions with a positive impact.
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product use, reinforcing evidence of unmet demand for MPTs
among many groups [11,12]. Results indicate that multi-pur-
pose prevention products are likely to be cost-effective among
younger women (aged 16–24) and FSWs compared to current
condom provision, with scenario 3, oral PrEP plus a MPT ring,
and scenario 5, the full range of MPT products, estimated to
be the most cost-effective. However, despite being cost-effec-
tive, our uptake projections suggest that products are unlikely
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Baseline condom use: +/–25%
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Product costs: 25th percentile/75th percentile
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ART coverage: 90%
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to achieve dramatic decreases in HIV incidence. Even if all
MPT products were introduced, incidence among older
women and FSWs is projected to reduce by just 8% (19%
among younger women), far under the estimated 48% reduc-
tion from achieving UNAIDS’ 90-90-90 target [57]. Although
MPTs offer a cost-effective option for tacking the HIV epi-
demic, a range of programmes will be required to reduce inci-
dence substantively.
The co-formulation or co-provision of products is likely to
increase programme cost-effectiveness for two reasons. First,
the multi-purpose nature of the products makes them more
attractive to potential users, increasing uptake and therefore
economies of scale from product use. Second, the costs asso-
ciated with unwanted pregnancies averted reduce the net
costs of the intervention overall, and increase benefits accrued
from averted maternal mortality. Incorporating STI prevention
does not markedly change cost-effectiveness estimates.
These estimates of cost-effectiveness are broadly compara-
ble to published studies, though there is considerable hetero-
geneity in these [20]. Although we base our counterfactual
scenario on empirical data from trials and nationally represen-
tative population based studies, our simple incidence model
predicts a higher number of annual infections than more com-
plex models, such as Thembisa and EPP/Spectrum models
[58,59]. The reason for this is uncertain, although it is worth
noting that the both models underestimate the 2012 HIV inci-
dence in South Africa compared to empirical estimates by
around 0.4 infections/100 person years among women aged
16–29 [60]. In addition, when incidence is varied in our sensi-
tivity analysis, our results are consistent with other models.
We note that the relatively low effectiveness figures observed
in topical PrEP trials (e.g. [5,61]) may reduce the likelihood of
governments investing in them, but incorporating additional
benefits such as contraception into partially effective products
may increase their chances of introduction.
This study has several limitations. First, we used a simple
static transmission model to estimate the short-term benefits
of introducing different products. This model does not con-
sider prevention benefits accruing into the future, including
the dynamic effect of reductions in incidence on prevalence.
However, this simplicity is also a strength because it gives
transparent estimations of the individual benefits of using
these products, resulting in estimates of impact and cost-
effectiveness similar to what would be produced from a trial.
Unfortunately, although dynamic transmission models can be
more realistic in capturing the longer-term benefits of an
intervention, their reliance on numerous assumptions, particu-
larly around the future dynamics of infection, makes their pro-
jections uncertain. Indeed, a recent analysis of 12 models for
South Africa showed that none were able to correctly predict
the future dynamics of infection between 2006 and 2011
[62]. Importantly, our use of a static model results in conser-
vative impact projections, as a dynamic model would predict
increased numbers of secondary infections averted with pro-
duct use. However, when new preventive methods are used
by a small proportion of the population, as predicted here,
total population protection has been shown similar to a static
model of efficacy multiplied by use [63], suggesting our model
projections may be fairly accurate.
Second, the model does not incorporate differential adher-
ence between products, although the one-way sensitivity
analysis shows that adherence could be less than 50% and
products still be cost-effective. Third, results are sensitive to
incidence assumptions, and 8 of the 10 cost-effective sce-
narios become cost-ineffective if low HIV incidence assump-
tions are used. However, a PSA shows that MPT scenarios
among FSWs and women aged 16–25 are 99% and 71%
likely to be cost-effective at the conservative $1,175 thresh-
old respectively. Fourth, we do not consider reductions in
paediatric HIV incidence due to unintended pregnancies
averted, making estimates conservative. Fifth, we consider
one-year estimates of cost and benefit from each scenario.
In reality, this may overestimate costs due to the potential
for economies of scale in delivery over time. Estimates of
benefit could also be overestimated, if uptake is graduated
over time leading to the level assumed here, or if adherence
was assumed to vary over time, reducing as a function of
length of use for example. Sixth, we estimate the costs of
multi-purpose products to be additive of that to single-pur-
pose products, which may underestimate the true cost of
products, particularly if co-formulated, in a real-world value-
based pricing framework. This means that our cost estimates
for MPTs may be too low, making MPTs seem more cost-
effective than they may be in reality, however since the esti-
mated costs of oral PrEP are substantively higher than
those observed in real-world demonstration projects (e.g.
[64]), the overall impact may be mitigated. Finally, although
single-purpose contraceptives are available for all delivery
mechanisms modelled (oral, injectable and topical products),
there is variation in which mechanisms are being developed
for co-formulation to provide multi-purpose prevention. The
introduction of a range of five MPTs is unlikely to occur in
reality.
This paper is also the first to use a discrete choice experi-
ment to predict product uptake within a cost-effectiveness
analysis in HIV, which allows us to explicitly consider hetero-
geneity in end-user preferences between different groups.
While DCE survey data were randomly sampled and
reweighted to match the age structure of the female South
African population, these data are unlikely to be generalizable
to the entire country or other countries. Furthermore, the
FSW data were collected through respondent driven sampling
(RDS) and, although reweighted, the highly variable nature of
sex work in South Africa makes reliable statements about gen-
eralisation difficult [45].
5 | CONCLUSIONS
This study estimates the cost-effectiveness of five candidate
MPTs, and finds that co-formulation or co-provision of contra-
ceptive and HIV prevention products would be an efficient
and effective use of resources among younger female groups
and FSWs at current levels of HIV incidence. Younger women
in particular find MPTs more attractive than single-purpose
technologies, suggesting that incorporating contraceptive
properties in HIV prevention products – or vice-versa – could
lead to substantive HIV and family planning benefits in this
group. These results strengthen calls for more research and
development in the co-formulation or co-provision of products
to reduce unmet need in sexual and reproductive health
services.
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